Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,501 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04595422 | Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines | recruiting | N/A | 800 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04783168 | Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study(AIRTECH) | recruiting | N/A | 240 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07220096 | Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes | recruiting | — | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02596490 | Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners | recruiting | N/A | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03948100 | Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers | recruiting | N/A | 400 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06688422 | Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy(INSPIRE-CRT) | recruiting | N/A | 100 | The Cooper Health SystemOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07020065 | Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% | recruiting | Phase 2 | 156 | Swiss Cancer InstituteOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07288034 | Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial | recruiting | Phase 2 | 535 | City of Hope Medical CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06141070 | Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease(ANDROMEDA) | recruiting | Phase 3 | 240 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 36 | Verismo TherapeuticsINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06992739 | Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)(PROTECT-2) | recruiting | Phase 2 | 49 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07528274 | Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529145 | Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment | recruiting | — | 90 | Medical University of BialystokOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT04937283 | Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | N/A | 690 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05313191 | Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors(ReRT) | recruiting | N/A | 1,800 | The New York Proton CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06342284 | Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer(PGHD) | recruiting | — | 40 | The New York Proton CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06503744 | Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer | recruiting | N/A | 110 | Shanghai Chest HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | recruiting | Phase 3 | 194 | Nuvation Bio Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06660407 | Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer | recruiting | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06865339 | Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer(TRIPL) | recruiting | Phase 2 | 76 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07195084 | To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer(HyPROS-LC) | recruiting | N/A | 12 | Anhui Provincial Cancer HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05445791 | Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations(METLUNG) | recruiting | Phase 3 | 312 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05852990 | Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC | recruiting | Phase 3 | 28 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06141369 | Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) | recruiting | N/A | 21 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06238882 | Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. | recruiting | N/A | 74 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06810375 | Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery | recruiting | Phase 3 | 120 | George Washington UniversityOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06928389 | Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer(NSCLC) | recruiting | Phase 3 | 536 | AkesoINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07291973 | Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures.(AURORA) | recruiting | N/A | 43 | Endowave Ltd.INDUSTRY | 2 | Apr 9, 2026 | clinicaltrials |
| NCT04849481 | The Research Plan of Taiwan Precision Medicine | recruiting | — | 550 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04919382 | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | recruiting | Phase 2 | 56 | Dwight OwenOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05281237 | Avecure Flexible Microwave Ablation Probe For Lung Nodules | recruiting | N/A | 10 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05713006 | Alectinib Pharmacokinetic in Patients With NSCLC | recruiting | Phase 1 / Phase 2 | 45 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements(DURABLE) | recruiting | Phase 1 / Phase 2 | 56 | Joshua PalmerOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06181812 | Pathogenic Variants in Genes Associated With Lung Adenocarcinoma | recruiting | — | 332 | Oscar Gerardo Arrieta RodríguezOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06248606 | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | recruiting | Phase 2 | 30 | Ryan Gentzler, MDOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07241767 | A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer | recruiting | Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07295821 | Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study(NSCLC) | recruiting | Phase 2 | 60 | AstraZenecaINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06079970 | Confocal Laser Endomicroscopy VERification(CLEVER) | recruiting | N/A | 208 | Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)OTHER | 5 | Apr 7, 2026 | clinicaltrials |
| NCT06080061 | Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer | recruiting | Phase 1 | 45 | Stanford UniversityOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 386 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514754 | Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients(GALENOS 2) | recruiting | N/A | 52 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 50 | Emory UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06545747 | Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI | recruiting | Phase 3 | 490 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07458425 | The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk | recruiting | N/A | 400 | University of Illinois at ChicagoOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07481786 | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 16, 2026source: clinicaltrials